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Abstract
Background: Few studies have formally assessed whether treatment outcomes have improved substantially over the years
for patients with extensive disease small-cell lung cancer (ED-SCLC) enrolled in phase III trials. The objective of the current
investigation was to determine the time trends in outcomes for the patients in those trials.
Methods and Findings: We searched for trials that were reported between January 1981 and August 2008. Phase III
randomized controlled trials were eligible if they compared first-line, systemic chemotherapy for ED-SCLC. Data were
evaluated by using a linear regression analysis. Results: In total, 52 trials were identified that had been initiated between
1980 and 2006; these studies involved 10,262 patients with 110 chemotherapy arms. The number of randomized patients
and the proportion of patients with good performance status (PS) increased over time. Cisplatin-based regimens, especially
cisplatin and etoposide (PE) regimen, have increasingly been studied, whereas cyclophosphamide, doxorubicin, and
vincristine–based regimens have been less investigated. Multiple regression analysis showed no significant improvement in
survival over the years. Additionally, the use of a PE regimen did not affect survival, whereas the proportion of patients with
good PS and the trial design of assigning prophylactic cranial irradiation were significantly associated with favorable
outcome.
Conclusions and Significance: The survival of patients with ED-SCLC enrolled in phase III trials did not improve significantly
over the years, suggesting the need for further development of novel targets, newer agents, and comprehensive patient
care.
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Introduction
Lung cancer is a leading cause of cancer-related mortality in
many industrialized countries. Small-cell lung cancer (SCLC),
which accounts for about 15% of all lung cancer cases, is
categorized into two clinical stages: limited disease (LD) and
extensive disease (ED). For patients with ED-SCLC, combination
chemotherapy is the mainstay of treatment.
In the 1980s, the most widely used combination of drugs for
initial treatment of ED-SCLC was cyclophosphamide, doxorubi-
cin, and vincristine (CAV), which produced a median survival time
of 9 to 11 months [1]. In the late 1980s, a combination regimen of
cisplatin and etoposide (PE) was introduced, and an alternating
regimen of PE and CAV has been widely investigated in
randomized controlled trials [2].
In 1999, the results of a systemic review indicated a modest
improvement over the years in the survival time of patients
with ED-SCLC treated with chemotherapy between 1972 and
1994 [3]. This improvement was potentially attributable to
(i) introduction of the PE regimen in the late 1980s and
(ii) improvements in the supportive care and general manage-
ment of the patients. However, this included just North American
trials and would provide some justification for looking at the
world-wide result.
A decade has passed since that systemic review, and recent
clinical trials have investigated newer antineoplastic agents such as
irinotecan and topotecan. Thus, we performed a literature search
to determine whether patient outcomes have improved in the
treatment of ED-SCLC.
Materials and Methods
Searching
We searched for trials that were reported between January 1981
and August 2008. To avoid publication bias, we identified both
published and unpublished trials through a computer-based search
of the PubMed database and abstracts from past conferences of the
American Society of Clinical Oncology (1998–2008). We used the
following search terms: lung neoplasm, carcinoma, small-cell, chemother-
apy, and randomized controlled trial. The search was guided by a
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review articles, relevant books, and the Physician Data Query
registry of clinical trials.
Selection
Phase III randomized controlled trials were eligible for inclusion
in this study if they compared first-line, systemic chemotherapy for
ED-SCLC that contained cytotoxic agents, providing the year of
trial initiation. Trials were excluded if they only investigated
immunotherapy regimens, or if they enrolled only responders to
the initial chemotherapy. Trials initially designed to assess
combined-modality treatment, including radiotherapy and surgery
concurrently undergone with the initial chemotherapy, were also
ineligible, but those optionally designed to conduct these therapies
or prophylactic cranial irradiation (PCI) sequentially after the
induction chemotherapy were allowed. Some phase III trials
incorporated patients with both LD-SCLC and ED-SCLC. These
were considered eligible only if survival data for patients with ED-
SCLC could be solely obtained. We acknowledge that the
definitions for LD-SCLC and ED-SCLC vary somewhat in the
different groups compared, and we could not strictly reallocate
each patient because we were unable to access the individual
patient databases. Instead, we applied the definition described in
each original report to this study. If no relevant descriptions were
documented, we considered that the definition in that trial would
have been based on the guidelines in existence at the time of that
trial initiation [4,5]. The control arms in each of the phase III
trials were identified based on statements in each trial.
Validity Assessment
To avoid bias in the data abstraction process, four medical
oncologists (I.O., N.O., Y.F., and K.H.), one of whom (K.H.)
holds a board certificate for medical oncology, independently
abstracted the data from the trials and subsequently compared
the results. All data were checked for internal consistency,
and disagreements were resolved by discussion among the
investigators.
Data Abstraction
The following information was obtained from each report: year
of trial initiation (i.e., year when the first patient was accrued);
number of patients enrolled and randomized; median age of
patients; proportion of patients with good performance status (PS);
proportion of patients who were male and who had brain
metastasis; chemotherapy regimen; definition of ED; description of
the administration of sequential thoracic irradiation, surgery, or
PCI as one of the trial designs; and median survival time (per
treatment arm).
Study Characteristics
All studies included were phase III randomized controlled trials
of first-line systemic chemotherapy for ED-SCLC. The study
outcomes were median survival time. Variation in study
characteristics and clinical heterogeneity between studies were
adjusted statistically (see below).
Quantitative Data Synthesis
Data from phase III trials were evaluated by using multiple,
stepwise regression analysis (with the following stepping method
criteria: probability of F to enter the model, ,0.05; to remove
from the model, .0.10). The data analyzed included year of trial
initiation, use of PE regimen, maximal age of patients, proportion
of patients with good PS, proportion of male patients, and
definition of PCI settings. These data were used to determine
whether each factor had an independent impact on the survival of
patients with ED-SCLC who were treated in the phase III studies
over time. All P values corresponded to 2-sided tests, and
significance was set at P,0.05.
Results
Trial Flow/Flow of Included Studies
Figure 1 shows a flow chart of this study. In total, 52 trials for
ED-SCLC were identified as a result of the computer-based and
manual searches for relevant articles, abstracts, and references
Figure 1. Flow chart showing the progress of trials through the review.
doi:10.1371/journal.pone.0007835.g001
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randomly to 110 chemotherapy arms.
Study Characteristics
Table 1 lists the baseline characteristics of the trials. Trials were
initiated between 1980 and 2006. The number of randomized
patients and the proportion of patients with good PS increased
over time (13.9 patient increase/year, P,0.001; and 1.32%
increase/year, P,0.001, respectively; Figures 2A and 2B), whereas
the proportion of male patients remained consistent (0.47%
decrease/year, P=0.114; Figure 2C). In 19 trials that assigned
PCI, it was planned that patients who achieved a complete
response (CR) or CR/partial response (PR) after induction
chemotherapy would receive PCI. Thirteen (25%) of the 52 phase
III trials showed a statistically significantly difference in survival
time. Of these, eight were in favor of the patient cohort that
received the experimental therapy compared with the control
group, while the remaining five were in favor of that in the control
group.
Types of Chemotherapy Arms
There were 110 chemotherapy treatment arms in the 52 phase
III trials (Table 2). Cisplatin-based regimens were the most
frequently investigated. The PE regimen, currently considered as
the standard treatment for patients with ED-SCLC, has
increasingly been studied (Figure 1). As expected, the CAV
alternating PE regimen was extensively examined in the 1980s, but
this decreased in the 1990s.
Trends in Patient Survival
Data on patient survival were available from all 52 trials and
110 chemotherapy arms and analyzed by treatment arm. A
scattergram of the two parameters (year of trial initiation and
median survival time) revealed that the slope of the fitted line was
0.021, indicating a 0.021 month (0.63 day) increase in median
survival time per year (P=0.272; Figure 3). Multiple regression
analysis, adjusting for several confounding trial characteristics, also
showed no significant association between the two parameters
(regression coefficient for year of trial initiation =0.011, 95%
confidence interval=20.36–0.38, P=0.950; Table 3). In this
setting, the proportion of patients with good PS was significantly
associated with a favorable outcome. The multiple regression
analysis also showed a significant influence of PCI setting on
survival prolongation. This finding is partly supported by a recent
report on the survival advantage of PCI in ED-SCLC patients who
responded to initial chemotherapy [6].
Discussion
Our results demonstrate no significant improvement in patient
outcomes over the years in phase III trials of systemic
chemotherapy for ED-SCLC, with an increase of 0.021 months
(0.63 days) per year (univariate analysis; P=0.272; Figure 3)
confirmed in the multivariate model (P=0.950; Table 3).
However, the proportion of patients with good PS and the trial
design of assigning PCI for those with CR or CR/PR significantly
influenced survival (Table 3).
The introduction of multiple drug regimens has been a great
advance in the treatment of ED-SCLC; indeed, the CAV regimen
yielded a survival time approximately twice as long as that of the
single-agent therapy frequently used in the early 1970s [1,7].
However, the survival benefit from chemotherapy has reached
somewhat of a plateau, even with the introduction of the PE
regimen in recent clinical trials, as compared with the CAV
regimen or CAV alternating PE [2,8,9,10]. In addition, most of
newer antitumour agents introduced after PE (e.g., irinotecan and
topotecan) failed to substantially prolong survival in the first-line
setting over the standard PE regimen [11,12,13,14,15]. Thus,
based on these findings, our main results demonstrate no
significant improvement in survival since 1980. In contrast, a
1999 study showed a significant increase in overall survival time
[3]. This difference in the time trend in overall survival is mainly
attributable to differences in the study period (year of trial
initiation: 1972–1994 vs. 1980–2006 in the earlier and present
study, respectively; [3]).
In Figure 3, trials between 2000 and 2005 appeared to show
extensive clustering with median survival time of around ten
months. It would be attributable to some common characteristics
among these trials, such as relatively uniformed chemotherapeutic
regimens (cisplatin-based ones) and larger number of the registered
patients. In contrast, there were other trial arms that yielded the
Table 1. Characteristics of the 52 Randomized Trials.
Variable Value
No. of trials 52
(No. of randomized patients in all trials 10262)
No. of treatment arms
24 7
34
41
Year of trial initiation
Median (range) 1990 (1980–2006)
No. of randomized patients (%)
,100 35
100–200 25
200–300 29
.300 11
Median (range) 158 (34–786)
Proportion of patients with good performance status{ (%)
,80 50
80–90 42
.90 8
Median percentage (range) 80 (35–100)
Male Patients (%)
,80 54
80–90 35
.90 11
Median percentage (range) 75 (56–93)
Trials assigning PCI for those with CR or CR/PR to the initial chemotherapy
Yes 37
No 63
Trials with a statistically significant difference in overall survival time (%)
Yes 25
No 65
Not recorded 10
{Defined as a performance status of 0 or 1.
Abbreviations; PCI, prophylactic cranial irradiation; CR, complete response; PR,
pertial response.
doi:10.1371/journal.pone.0007835.t001
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months). These included less number of the enrolled patients,
which possibly resulted in a wide-range distribution in the Figure.
We investigated a similar issue previously [16], namely trends in
prognosis over the years in chemo-naı ¨ve patients with advanced
non-small cell lung cancer (NSCLC) enrolled in phase III trials.
Figure 2. Trends in trial characteristics. These charts show the associations between year of trial initiation and number of randomized patients
(A), proportion of patients with good PS (B), and proportion of male patients (C) in each trial. The size of solid circles represents data weighted on the
basis of the number of randomized patients. Abbreviations: PS, performance status.
doi:10.1371/journal.pone.0007835.g002
Table 2. Types of Chemotherapy Arms and Treatment Outcomes (Per Treatment Arm).
Chemotherapy Arm No. of Arms (%) MST [range], months
Total no. of arms 110 9.3 [4.9–14.5]
Platinum-based regimens 78 (70.9) 9.5 [4.9–14.5]
Cisplatin-based 64 (58.2) 9.6 [5.8–14.5]
CAV alternating PE 16 (14.5) 9.5 [5.8–14.5]
PE 16 (14.5) 9.4 [7.0–10.2]
Other Cisplatin-based 32 (29.1) 9.8 [6.7–12.8]
Nonplatinum regimens 32 (29.1) 8.5 [5.0–13.0]
CAV-based 10 (9.1) 9.1 [7.5–13.8]
Non-CAV-based combination therapy 19 (17.3) 8.2 [5.0–13.0]
Non-CAV-based monotherapy 3 (2.7) 8.3 [6.0–9.3]
Abbreviations: MST, median survival time; CAV, cyclophosphamide, doxorubicin, and vincristine; PE, cisplatin and etoposide.
doi:10.1371/journal.pone.0007835.t002
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survival (3.61 days per year) but one that was statistically
significant in the multiple regression model (P,0.001; ([16]).
There may be several potential factors behind such differences in
statistical results in SCLC and NSCLC settings. The most
important is that new active agents such as taxanes appeared in
the treatment of NSCLC [17,18] and few novel agents, including
molecular-targeted agents, did in the treatment for SCLC
[11,19,20,21] in these study periods. Another hypothesis is that
advanced NSCLC might be more influenced than SCLC by lead
time bias through early detection with improved imaging
techniques, mainly because the growth rate of NSCLC is generally
less rapid than that of SCLC throughout its natural history [22].
Progress in supportive care practices would lead to improvements
in survival among patients with advanced NSCLC. Those with
advanced NSCLC usually have less rapid disease progression and,
thus, would likely benefit from its advancement. Finally, the
statistical difference between our NSCLC and SCLC studies could
have arisen from differences in sample size (number of trials),
indicating that the current study may have lacked adequate power
to accurately evaluate the association between the year of trial
initiation and patient outcome.
The potential influence of second-line chemotherapy should
also be considered in assessing the effect of first-line chemotherapy
because it may contribute to recent improvements in survival [23].
The trials analyzed here rarely provided information about
second-line treatment, and we can not assess its exact effect in
this setting. There are few positive phase III trials of second-line
treatments, and thus it is unlikely that such therapy can
significantly confound patient prognosis after the initiation of
first-line chemotherapy [24].
In conclusion, the results of our analysis suggest that, regardless
of the reason, the survival of patients with ED-SCLC who were
enrolled in phase III trials did not improve significantly over the
years. Thus, the development of novel targets, newer agents, and
comprehensive patient care will be essential in the future fight
against lung cancer.
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